Algernon Pharmaceuticals Looks to Highly Regarded UK Company to Conduct Phase 1 DMT Stroke Study


Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive in a discussion regarding news that the Company has chosen renowned contract research organization Hammersmith Medicines Research, located in the UK, to conduct their Phase 1 Stroke Program study using DMT.

Mr. Moreau talks about the study and also the type of licensing this facility has to have to be able to do this type of testing.